A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease.
Maslak
P G
PG
Dao
T
T
Gomez
M
M
Chanel
S
S
Packin
J
J
Korontsvit
T
T
Zakhaleva
V
V
Pinilla-Ibarz
J
J
Berman
E
E
Scheinberg
D A
DA
D000328:Adult; D000368:Aged; D000595:Amino Acid Sequence; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000737:chemistry*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010865:Pilot Projects
D019496:Cancer Vaccines; D016044:Fusion Proteins, bcr-abl